Compounds > indazoles
Page last updated: 2024-08-21

indazoles and ER-Negative PR-Negative HER2-Negative Breast Cancer

indazoles has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's12 (85.71)24.3611
2020's2 (14.29)2.80

Authors

AuthorsStudies
Lin, J; Yang, X; Zhao, H1
Bhat, V; Cescon, DW; Cruickshank, J; Hodgson, K; Parsyan, A; Pellizzari, S; Wakeham, D1
Mountzios, G; Papadimitriou, CA; Papadimitriou, M1
Kerbel, RS; Man, S; Reguera-Nuñez, E; Xu, P1
Ding, M; Fan, X; Fu, W; Hu, S; Lei, C; Li, T; Lin, F; Liu, S; Shen, Y; Tang, Y; Yang, Y; Ye, X; Yu, Y1
Chen, P; Cui, D; He, J; Huang, D; Jiang, L; Li, L; Ma, T; Qi, J; Schmitt, CA; Shao, S; Tao, R; Wang, J; Wu, C; Xiong, J; Yu, D; Yu, Y; Zhou, B1
Chrysikos, D; Dimopoulos, MA; Papadimitriou, CA; Psaltopoulou, T; Sergentanis, TN; Zagouri, F1
Aceto, N; Auricchio, N; Barber, P; Baselga, J; Bergamaschi, A; Bosch, A; Carey, LA; Castel, P; Elkabets, M; Ellis, H; Hazra, S; Juric, D; Kim, P; Lewis, JS; Maheswaran, S; Morse, N; Ng, T; Penault-Llorca, F; Perou, CM; Radosevic-Robin, N; Scaltriti, M; Singh, S; Tao, JJ; Viola-Villegas, NT; Vojnovic, B; Weitsman, G1
Chen, K; Gaur, S; Hu, S; Liu, YR; Pan, SL; Tzeng, HE; Wang, Y; Yang, L; Yen, Y1
Bartholomeusz, C; Hortobagyi, GN; Kai, K; Kondo, K; Masuda, H; Pitner, MK; Reyes, ME; Saya, H; Sen, S; Torres-Adorno, AM; Tripathy, D; Ueno, NT; Wang, X; Xie, X1
Bocci, G; Di Desidero, T; Kerbel, RS; Man, S; Xu, P1
Beijersbergen, RL; de Lint, K; Jastrzebski, K; Lieftink, C; Poell, JB; Soueidan, H; Vidal Rodriguez, J; Wessels, LF1
Carlson, JH; De, P; Dey, N; Leyland-Jones, B; Marcus, A; Wu, H1
Reed, DE; Shokat, KM1

Reviews

2 review(s) available for indazoles and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
    Cancer treatment reviews, 2018, Volume: 67

    Topics: Benzamides; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms

2018
Hsp90 inhibitors in breast cancer: a systematic review.
    Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:5

    Topics: Adenine; Antineoplastic Agents; Benzamides; Benzoquinones; Biomarkers, Tumor; Female; Glycine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Indazoles; Isoxazoles; Lactams, Macrocyclic; Pyridines; Resorcinols; Triazoles; Triple Negative Breast Neoplasms

2013

Other Studies

12 other study(ies) available for indazoles and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab.
    JAMA oncology, 2020, 03-01, Volume: 6, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Humans; Indazoles; Mutation; Piperidines; Recombinational DNA Repair; Triple Negative Breast Neoplasms

2020
Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer.
    Breast (Edinburgh, Scotland), 2021, Volume: 58

    Topics: Cell Line, Tumor; Cell Proliferation; Humans; Indazoles; Indoles; Protein Serine-Threonine Kinases; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2021
Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models.
    Angiogenesis, 2018, Volume: 21, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kidney Neoplasms; Mice; Mice, SCID; Mice, Transgenic; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2018
EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 05-01, Volume: 25, Issue:9

    Topics: Animals; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins c-akt; Receptors, Notch; Sulfonamides; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019
Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
    Theranostics, 2019, Volume: 9, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cancer Survivors; Cell Line, Tumor; Cellular Senescence; DNA Methylation; DNA, Neoplasm; Doxorubicin; Drug Delivery Systems; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Mice, Nude; Mixed Function Oxygenases; Proto-Oncogene Proteins; Pyridones; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2019
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
    Science signaling, 2014, Mar-25, Volume: 7, Issue:318

    Topics: Antibodies, Monoclonal, Humanized; Blotting, Western; Cell Line, Tumor; Cetuximab; Dimerization; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Immunoglobulin G; Indazoles; Neuregulin-1; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor, ErbB-3; Signal Transduction; Sulfonamides; Triple Negative Breast Neoplasms

2014
The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Oncotarget, 2015, May-10, Volume: 6, Issue:13

    Topics: Animals; Apoptosis; beta Catenin; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Humans; Indazoles; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Wnt Proteins; Xenograft Model Antitumor Assays

2015
Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; Mice; Piperazines; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2015
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
    Oncotarget, 2015, Dec-15, Volume: 6, Issue:40

    Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Female; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indazoles; Kaplan-Meier Estimate; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Pyrimidines; Real-Time Polymerase Chain Reaction; Sulfonamides; Topotecan; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2015
Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Humans; Indazoles; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Sulfonamides; Triple Negative Breast Neoplasms

2016
Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    Oncotarget, 2016, Jul-12, Volume: 7, Issue:28

    Topics: Adenomatous Polyposis Coli Protein; beta Catenin; Brain Neoplasms; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dishevelled Proteins; Female; Fibronectins; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Indazoles; Integrins; Matrix Metalloproteinase 7; Microscopy, Confocal; Microscopy, Fluorescence; Microscopy, Video; Mutation; Phenotype; RNA Interference; RNA, Small Interfering; Sulfonamides; Sulindac; Triple Negative Breast Neoplasms; Up-Regulation; Wnt Proteins; Wnt Signaling Pathway

2016
INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.
    Molecular cancer research : MCR, 2017, Volume: 15, Issue:6

    Topics: Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Female; Humans; Indazoles; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Phosphates; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sulfonamides; Triple Negative Breast Neoplasms

2017